About
Unlocking the therapeutic potential of mimicry
What if we could engineer therapeutics to trigger the ideal biological response by taking inspiration from mimicry in nature?
Mimicry is one of nature’s oldest tricks in which organisms gain adaptive advantages by imitating others.
We adapted this idea to drug discovery. MIMIC™, our computationally driven bioplatform that couples machine learning with molecular mimicry, engineers therapeutics to trigger a desired biological response.
Our MIMIC platform opens the possibility to develop engineered medicines with specific features to access a range of targets, including those that were previously intractable.
Founded by Flagship Pioneering in 2021, Metaphore aims to unlock breakthroughs that outperform today’s drugs for maximum patient impact.
Leadership Team
Founding Team
Advisors
Arup Chakraborty, PhD
Scientific Advisor and Academic Partner, Flagship Pioneering
Institute Professor at MIT
Founding Steering Committee Member, Ragon Institute
Daniel Lingwood, PhD
Associate Professor of Medicine, Harvard Medical School
Core Member, Ragon Institute
Ulrich von Andrian, MD
Edward Mallinckrodt Jr. Professor of Immunopathology, Microbiology and Immunobiology, Harvard Medical School
Senior Investigator, von Adrian Lab, Boston Children’s Hospital
Timothy Whitehead, PhD
Associate Professor of Chemical and Biological Engineering, University of Colorado Boulder